about
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibitionNa(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCTUnregulated smooth-muscle myosin in human intestinal neoplasiaMutations in the circadian gene CLOCK in colorectal cancerMetastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal CancerThe intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent mannerRHOA inactivation enhances Wnt signalling and promotes colorectal cancer.Application of gene expression profiling to colon cell maturation, transformation and chemoprevention.Brush border myosin Ia has tumor suppressor activity in the intestine.Customizing chemotherapy for colon cancer: the potential of gene expression profiling.Myo5b knockout mice as a model of microvillus inclusion disease.Human SMC2 protein, a core subunit of human condensin complex, is a novel transcriptional target of the WNT signaling pathway and a new therapeutic target.c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis.HDAC4 promotes growth of colon cancer cells via repression of p21.EPH receptors in cancer.Apigenin protects endothelial cells from lipopolysaccharide (LPS)-induced inflammation by decreasing caspase-3 activation and modulating mitochondrial functionAn A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expressionInvestigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.Loss of the EPH receptor B6 contributes to colorectal cancer metastasisExpression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer.Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.7q deletion mapping and expression profiling in uterine fibroids.Villin expression is frequently lost in poorly differentiated colon cancer.Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.Cancer stem cells and personalized cancer nanomedicine.Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells.PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.Candidate driver genes in microsatellite-unstable colorectal cancer.The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.Transforming pathways unleashed by a HDAC2 mutation in human cancer.EPHB4 and survival of colorectal cancer patients.Mutations in two short noncoding mononucleotide repeats in most microsatellite-unstable colorectal cancers.Tumor necrosis factor-alpha related gene response to Epothilone B in ovarian cancer.Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin.Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression.A gene expression profile that defines colon cell maturation in vitro.
P50
Q24321639-5CFD817E-5F8E-47EF-BEF7-D4F2104838ACQ24545763-4224BEF2-0AFD-46BD-A87F-F22F899D2051Q24657391-E1AA2B25-E1FC-41BF-877C-19EB1869540AQ28285422-C675026A-9E2A-4E6F-8567-FA7D844DC787Q34062558-AA780054-B881-477D-955B-97266729971BQ34139192-203A7D81-7D5C-4212-B6E2-9162A4DDE888Q34628925-5217FAB4-48BD-49E8-9761-F3264F26BEFEQ35168689-1952B64B-063D-426E-9DA1-368909750419Q35749872-B6DC6E57-8994-426D-B0E9-DB2879AD2922Q35856974-E27CFFD0-9725-4866-9CF0-A1A0EFC662A0Q35880786-E0B83F83-D161-4CC5-890E-62F1BA45300AQ36481765-0BABADF2-3ED7-483E-AB44-EBA63E3AE53BQ36671497-3B481406-9419-446D-B377-1CDA917EE866Q36914284-9102AC6A-77E0-45BE-8F63-09DF61EF4CA3Q37170873-2CBF761B-F2BE-4059-8ED6-5D090F3CE523Q37225063-A11837B3-1F07-4A54-BC6F-60FE372FEE35Q37448192-ACC3E89E-9AE5-48C0-A0B4-0F36BDBB4F95Q37627879-4C8620BF-BC00-4450-AB72-B3FD0AEC15CBQ37681807-3FCF2CEA-6EF7-40BC-AEFE-E0317F39DB85Q38291495-0C351AD8-9AA9-4C53-83F3-FDF34C49760CQ38321431-78A4BB8A-9F66-4D08-8235-0CABDFFD8353Q38325322-0C240503-BF6F-46DD-88E0-EB64D0BD2581Q38327592-71423F7B-F3B6-4D7B-B121-697E70D649EFQ38345083-2C28A83A-F65B-42CA-B826-5C2BC26AA80EQ38584695-C045CBA0-D32F-48CF-AD71-6528154C31DBQ38702970-6D1EEBD5-6DF0-4844-836E-E44B1CFAB261Q38785795-FF40E02A-8BE7-42B2-8FAA-8145483907FDQ38799295-DCBCE7B1-8FAE-461D-8BF4-635DC877E241Q38846958-C93F5E78-915A-433D-94C8-4D08E111164CQ38892146-46E537FA-DFE0-4705-9880-95D5D59A7329Q39001975-14FFBD72-7D8E-488C-8180-9DE90C8A7C47Q39547630-53164A64-DFF7-44E2-A0F9-1E0A4BA9821BQ39801979-3689E0C5-5D0B-45C8-BB15-FCADA707E5E6Q40014673-FE82D852-659A-4C17-A678-6139F0E91A6DQ40230554-6625ED2F-C1DE-4D55-A99B-9937EF3C0C45Q40414565-51707D1D-F30A-4A6E-AA85-B7449E804D58Q40572985-D9320544-A511-4A8F-A95B-E889A48483F3Q40604120-97D77158-6373-4B63-97B8-AB863B4FD3F2Q40634782-80B5FF15-1D22-4905-B4C4-C89D6BD797EAQ40710198-1E42A7A9-4511-49B3-94B7-5143109EFD45
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Diego Arango
@ast
Diego Arango
@en
Diego Arango
@es
Diego Arango
@nl
Diego Arango
@sl
type
label
Diego Arango
@ast
Diego Arango
@en
Diego Arango
@es
Diego Arango
@nl
Diego Arango
@sl
prefLabel
Diego Arango
@ast
Diego Arango
@en
Diego Arango
@es
Diego Arango
@nl
Diego Arango
@sl
P1053
M-5667-2016
P106
P21
P31
P3829
P496
0000-0003-2953-3284